ErbB-2 overexpression in breast tumors is associated with poor survival. Expression of Notch-1 and its ligand, Jagged-1, is associated with the poorest survival, including ErbB-2-positive tumors. Trastuzumab plus chemotherapy is the standard of care for ErbB-2-positive breast cancer. A proportion of tumors are initially resistant to trastuzumab and acquired resistance to trastuzumab occurs in metastatic breast cancer and is associated with poor prognosis. Thus, we investigated whether Notch-1 contributes to trastuzumab resistance. ErbB-2-positive cells have low Notch transcriptional activity compared to non-overexpressing cells. Trastuzumab or a dual epidermal growth factor receptor (EGFR)/ErbB-2 tyrosine kinase inhibitor (TKI) increased Notch activity by 2-to 6-fold in SKBr3, BT474 and MCF-7/HER2-18 cells. The increase in activity was abrogated by a Notch inhibitor, c-secretase inhibitor (GSI) or Notch-1 small-interfering RNA (siRNA). Trastuzumab decreased Notch-1t precursor, increased amount and nuclear accumulation of active Notch-1 IC and increased expression of targets, Hey1 and Deltex1 mRNAs, and Hes5, Hey1, Hes1 proteins. Importantly, trastuzumab-resistant BT474 cells treated with trastuzumab for 6 months expressed twofold higher Notch-1, twofold higher Hey1, ninefold higher Deltex1 mRNAs and threefold higher Notch-1 and Hes5 proteins, compared to trastuzumab-sensitive BT474 cells. The increase in Hey1 and Deltex1 mRNAs in resistant cells was abrogated by a Notch-1 siRNA. Cell proliferation was inhibited more effectively by trastuzumab or TKI plus a GSI than either agent alone. Decreased Notch-1 by siRNA increased efficacy of trastuzumab in BT474 sensitive cells and restored sensitivity in resistant cells. Trastuzumab plus a GSI increased apoptosis in sensitive cells by 20-30%. A GSI alone was sufficient to increase apoptosis in trastuzumab-resistant BT474 cells by 20%, which increased to 30% with trastuzumab. Notch-1 siRNA alone decreased cell growth by 30% in sensitive and more than 50% in resistant BT474 cells. Furthermore, growth of both trastuzumab sensitive and resistant cells was completely inhibited by combining trastuzumab plus Notch-1 siRNA. More importantly, Notch-1 siRNA or a GSI resensitized trastuzumabresistant BT474 cells to trastuzumab. These results demonstrate that ErbB-2 overexpression suppresses Notch-1 activity, which can be reversed by trastuzumab or TKI. These results suggest that Notch-1 might play a novel role in resistance to trastuzumab, which could beIntroduction Overexpression (Slamon et al., 1987) or hyperactivity of human epidermal growth factor receptor (EGFR)-2 (HER2/neu or ErbB-2) protein (Menendez et al., 2006) occurs in 25-30% of breast cancers. ErbB-2 is a type-I transmembrane receptor tyrosine kinase that is activated by growth factor-independent homodimerization or growth factor (that is, EGF, transforming growth factor-a, heregulin)-dependent heterodimerization with EGFR, ErbB-3 or ErbB-4. ErbB-2 activation results in tyrosine phosphorylation and transmission of intracellular signals that stimulate survival and proliferation (Yarden, 2001 ). ErbB-2-positive breast tumors are associated with poor prognosis, aggressive behavior (Slamon et al., 1987 (Slamon et al., , 1989 and/or resistance to some types of cytotoxic (Yokoyama et al., 2005) and endocrine therapies (Osborne et al., 2003; Shou et al., 2004; Arpino et al., 2005) .
Trastuzumab (Herceptin) is a humanized monoclonal antibody that recognizes the extracellular domain of ErbB-2 (Carter et al., 1992) . Trastuzumab blocks ErbB-2 at the cell surface, inhibits receptor-receptor interaction, activation and signaling to slow growth (Sliwkowski et al., 1999; Baselga et al., 2001; Nagata et al., 2004; Nahta and Esteva, 2006) . Trastuzumab is most effective in women having tumors that have ErbB-2 gene amplification (Muss et al., 1994; Nabholtz and Slamon, 2001; Slamon et al., 2001; Vogel et al., 2002) . The overall response rate (RR) of women diagnosed with ErbB-2-positive, metastatic breast cancer and treated with trastuzumab as a single first-line agent was only 26% (Vogel et al., 2002) . Overall RRs increased significantly when trastuzumab was combined with cytotoxic chemotherapy, such as anthracyclines (RR ¼ 56%; Slamon et al., 2001) , taxanes (RR ¼ 67-81%; Seidman et al., 2001) or vinorelbine (RR ¼ 60%; Burstein et al., 2001 Burstein et al., , 2003 Jahanzeb et al., 2002; Papaldo et al., 2006) . However, the rate of de-novo resistance to trastuzumab in ErbB-2-overexpressing metastatic breast cancer ranged from 66 to 88% (Cobleigh et al., 1999; Vogel et al., 2002) . In addition, most women with metastatic breast cancer who responded initially to trastuzumab developed acquired resistance within the first year. Conversely, when trastuzumab was combined with chemotherapy in the adjuvant setting, only 10-15% of women developed distant metastases (Romond et al., 2005; Amar et al., 2008) . The molecular mechanisms responsible for denovo and/or acquired resistance to trastuzumab are poorly understood. ErbB-2 protein expression is maintained, suggesting alterations in downstream signaling pathways. ErbB-2 may be sterically hindered from interacting with trastuzumab. Increased MUC4, a membrane-associated glycoprotein, binds to ErbB-2 and hinders the attachment of ErbB-2 to trastuzumab (Price-Schiavi et al., 2002) . Increased expression of insulin-like growth factor 1 receptor (IGF-1R) has been shown to decrease growth inhibition mediated by trastuzumab (Lu et al., 2004) . Blockade of IGF-1R restored trastuzumab sensitivity in-vitro cell models (Nahta et al., 2005) . Moreover, women with phosphatase and tensin homologue deleted on chromosome 10 (PTEN, a phosphoinositide-3 kinase phosphatase)-deficient ErbB-2-positive breast tumors may have poorer RRs to trastuzumab. Thus, loss of PTEN might predict trastuzumab resistance (Nagata et al., 2004) . Recently, a dual EGFR/ErbB-2 tyrosine kinase inhibitor (TKI), lapatinib (Tykerb or GW57016) has been approved for the treatment of ErbB-2-positive metastatic breast cancer resistant to trastuzumab (Geyer et al., 2006) . However, resistance to lapatinib occurs in vitro (Xia et al., 2006) . Thus, we would anticipate that resistance to TKIs may become a clinical problem similar to resistance to trastuzumab. Therefore, identifying novel signaling pathways that decrease the efficacy of ErbB-2-targeted treatments will be critical to prevent or treat resistance.
Notch receptors are potent cell-fate regulatory proteins. Notch receptors act as survival factors that promote breast cancer (Dievart et al., 1999; Politi et al., 2004) . Active Notch-1 (Stylianou et al., 2006) or Notch-4 (Imatani and Callahan, 2000) cause mammary tumors in mice. In humans, high coexpression of Notch-1 and its ligand, Jagged-1, in breast cancer is associated with poor overall survival. This includes cancers overexpressing ErbB-2 (Reedijk et al., 2005; Dickson et al., 2007) . Furthermore, Notch-1 could be important for mammary epithelial stem cells (Dontu et al., 2004) and for ductal carcinoma in situ-derived 'cancer stem cells' (Farnie et al., 2007) . Notch-1 protects CD24(À/low)/ CD44 þ putative breast cancer-initiating cells from radiation (Phillips et al., 2006) .
There are four mammalian Notch receptors (1, 2, 3, and 4) with five ligands (Delta-like 1, 3 and 4, and Jagged 1 and 2; Weinmaster, 1997; Miele, 2006; Miele et al., 2006) . Both ligands and receptors are type-I membrane proteins. Cell-cell contact is required for Notch activation by ligand binding. Notch-ligand interactions regulate cell fate during cell-cell contact (Artavanis-Tsakonas et al., 1999; Miele and Osborne, 1999) . Notch receptors are heterodimeric proteins that are synthesized as single polypeptide precursors. The polypeptide is cleaved by a furin-like proteinase (S1 cleavage) in the trans-Golgi into two subunits, extracellular Notch (N EC ) and transmembrane Notch (Nt; Blaumueller et al., 1997; Logeat et al., 1998) . Upon ligand binding, the interaction between heterodimers N EC and Nt is destabilized resulting in endocytosis of N EC associated with the ligand (Lindsell et al., 1995; Mumm et al., 2000) within the ligand-expressing cell. This process has been shown to be critical for Notch activation (Parks et al., 2000) . Dissociation of N EC triggers an S2 cleavage in the extracellular region catalysed by a disintegrin and metalloproteinase (ADAM10 or ADAM17; Brou et al., 2000; Mumm et al., 2000) . Then, an S3 cleavage within the Notch transmembrane domain is catalysed by g-secretase, a multi-subunit enzyme complex whose catalytic subunit is presenilin-1 or -2 (Mumm et al., 2000) . This releases an intracellular domain (N IC ), which is transferred into the nucleus, where it modulates transcription via CSL (mammalian CBF-1/Drosophila suppressor of hairless/ Caenorhabditis elegans Lag-1) transcription factors (Schroeter et al., 1998) . Notch signaling may contribute to breast tumorigenesis by inhibiting differentiation, promoting survival and/or increasing proliferation. Potential targets of Notch-1 include cyclins D1 and D3 (Ronchini and Capobianco, 2001; Sicinska et al., 2003) , cyclin A (Baonza and Freeman, 2005) , phosphatidylinositol 3-kinase (Calzavara et al., 2007) , AKT (Rangarajan et al., 2001) , nuclear factor-kB (Oswald et al., 1998) and c-Myc (Weng et al., 2006; Efstratiadis et al., 2007) .
In this study, we investigated cross-talk between ErbB-2 activity and Notch-1 to determine the role of Notch-1 in ErbB-2-positive breast cancer and in resistance to trastuzumab. The results demonstrated that ErbB-2-overexpressing breast cancer cell lines have low Notch activity. Inhibition of ErbB-2 in trastuzumab-sensitive cells increases Notch-1 activity. Furthermore, trastuzumab-resistant cells express higher Notch-1 and endogenous Notch-1 targets. Consequently, cell proliferation of both trastuzumab-sensitive and -resistant ErbB-2-positive breast cancer cells was decreased more effectively and apoptosis increased in Figure 1b , upper panels), it increased Notch transcriptional activity twofold in SKBr3, fivefold in BT474 and almost twofold in MCF-7/HER2-18 breast cancer cells (Figure 1b , lower panels). Interestingly, the increase in Notch transcriptional activity by trastuzumab directly correlated with the effectiveness of trastuzumab in decreasing the extent of ErbB-2 tyrosine phosphorylation, which suggested that the kinase activity of ErbB-2 might be regulating Notch activity. To specifically address this question, we treated SKBr3 cells with a dual EGFR/ ErbB-2 TKI (4557W, 4-(4-benzyloxyanilino)-6,7-dimethoxyquinazoline). A TKI decreased ErbB-2 tyrosine phosphorylation by threefold (Figure 1b, upper panel) and increased Notch transcriptional activity by threefold ( Figure 1b , lower panel). These results, taken together, suggest that inhibition of ErbB-2 kinase activity by trastuzumab or a TKI increases Notch transcriptional activity in ErbB-2-positive breast cancer cells.
To determine whether the trastuzumab-induced increase in CBF-1 reporter activity was due to specifically Notch-1, we used both pharmacologic and genetic approaches.
A specific g-secretase inhibitor (LY411,575) that prevents cleavage of Notch precursor (Notch-1t) to active Notch-1 IC completely abrogated the trastuzumab-induced increase in CBF-1 reporter activity (Figure 2a ). Furthermore, a Notch-1 siRNA that almost completely abolished Notch-1 protein expression (Figure 2b , right panel) prevented the increase in CBF-1 reporter activity by trastuzumab (Figure 2b , left panel). These results suggested that trastuzumab specifically increased Notch-1 transcriptional activity in SKBr3 cells.
ErbB-2 inhibition decreases Notch-1t, increases amount and nuclear localization of Notch-1 IC and expression of endogenous Notch targets. We measured expression of Notch-1 and downstream target mRNAs and proteins in SKBr3 cells in response to trastuzumab by real-time PCR and western blot. Trastuzumab increased mRNA expression of two Notch-1 targets, Hey1 by twofold and Deltex1 by fourfold ( Figure 3a) . Furthermore, trastuzumab decreased the Notch-1t precursor (Figure 3b ), increased protein expression of three endogenous Notch-1 targets, Hes5, Hey1, and Hes1 (Figure 3b ), and active Notch-1 IC protein by almost fourfold compared to immunoglobulin G (IgG) treatment (Figure 3c ). These results support the hypothesis that activation of CBF-1 reporter activity (Figures 1 and 2 ) corresponds to a true increase in Notch-1-dependent transcriptional activity at the genomic level.
In addition, we determined the cellular localization of Notch-1 by immunofluorescence microscopy. The results demonstrated that Notch-1 accumulates in the nucleus in 90% of SKBr3 ( Figure 4a ) and 50% of MCF-7/HER2-18 cells ( Figure 4b ) in response to trastuzumab. To provide biochemical confirmation of this observation, we transfected full-length human Notch-1 fused at the C terminus with Renilla luciferase (Vooijs et al., 2004) , and isolated nuclei from SKBr3 and MCF-7/ HER2-18 cells treated with IgG or trastuzumab to quantify the amount of Notch-1 in the nuclear fraction as measured by Renilla luciferase output. Our data showed that trastuzumab-treated SKBr3 cells contained 20-fold more nuclear Notch-1 (Figure 4c ), and MCF-7/ HER2-18 cells contained 10-fold more nuclear Notch-1 (Figure 4d ) than IgG-treated cells. These results suggest that inhibition of ErbB-2 activates Notch-1 signaling by regulating the posttranslational processing of Notch-1 upstream of Notch-1 IC formation and nuclear accumulation.
Trastuzumab-resistant cells express higher Notch-1 and Notch-1 targets
The data presented so far demonstrated that Notch-1 activity was increased in trastuzumab-sensitive ErbB-2-positive breast cancer cells. To determine whether the increase in Notch-1 activity was relevant to trastuzumab resistance, we measured expression of Notch-1 and endogenous target genes (Miele, 2006) , Hey1 and Deltex1 mRNAs, and Notch-1 and Hes5 proteins in both parental trastuzumab-sensitive BT474 cells and a resistant BT474-derived cell line which was treated for 6 months with trastuzumab and developed resistance. Resistance was ascertained by measuring cell proliferation using a DNA-based assay in response to increasing concentrations of trastuzumab (0-80 mg/ml once per month until the IC 50 of trastuzumab was calculated to be greater than 80 mg/ml) (data not shown). First, Notch-1 mRNA was increased approximately twofold by trastuzumab in a time-dependent manner in trastuzumab-sensitive SKBr3 ( Figure 5a ) and BT474 cells (Figure 5b ). The twofold increase in Notch-1 mRNA was maintained in trastuzumab-resistant BT474 cells after 6 months of treatment ( Figure 5b ). Furthermore, trastuzumab-resistant BT474 cells expressed twofold higher Hey1 (Figure 5c ), ninefold higher Deltex1 ( Figure 5d ) mRNAs and threefold higher Hes5 (Figure 5e ) protein, all endogenous Notch-1 targets, compared to trastuzumab-sensitive BT474 cells. The increase in Hey1 and Deltex1 mRNAs was abrogated by decreasing Notch-1 protein ( Figure 5f ) using a specific Notch-1 siRNA (Figures 5c and d) . These results strongly indicate that Notch-1 expression and activity are increased by trastuzumab during short-term treatment and in trastuzumab-resistant cells selected after long-term treatment.
ErbB-2-positive breast cancer cell growth is more effectively inhibited by trastuzumab/TKI plus GSI than by either agent alone To determine the consequence of Notch-1 activation by ErbB-2 inhibition, we measured cell proliferation in response to trastuzumab, a dual EGFR/ErbB-2 TKI and/or a Notch inhibitor (GSI) using an in vitro DNAbased assay and two chemically distinct GSIs, namely, LY411,575 and MRK-003, which inhibit Notch-1 transcriptional activity as measured by CBF-1 luciferase reporter assays and expression of endogenous genes, Hey1, Deltex1 and Hes5 (data not shown). Consistent with the observation that ErbB-2 overexpression decreases Notch-1 activity, overexpression of ErbB-2 Overexpression of ErbB-2 inhibits Notch activity, which is reversed by trastuzumab or a tyrosine kinase inhibitor (TKI). (a) CBF-1 luciferase reporter assays were performed as described in 'Materials and methods' to detect Notch transcriptional activity in breast cancer cell lines endogenously overexpressing ErbB-2 (SKBr3 and BT474), stably overexpressing ErbB-2 (MCF-7/HER2-18) or moderately expressing ErbB-2 (MCF-7/Neo, MDA-MB-231). (b, upper panel) Western blot analysis to detect tyrosine-1248 phosphorylated ErbB-2 and total ErbB-2 protein in MCF-7/Neo, MCF-7/HER2-18, SKBr3 and BT474 cells in response to immunoglobulin G (IgG) control versus 10 mg/ml trastuzumab treatment, or vehicle control versus 4 mM TKI treatment. Densitometry was performed to quantify PY-ErbB-2 and total ErbB-2 protein. The ratio of PY-ErbB-2/total ErbB-2 protein is shown below western blot panels. (b, lower panel). CBF-1 luciferase reporter assays were performed for MCF-7/Neo and MCF-7/HER2-18 cells. Independently, SKBr3, BT474, MCF-7/HER2-18 cells were transfected with a CBF-1 luciferase reporter construct and then treated with 20 mg/ml IgG versus trastuzumab; or vehicle control versus 4 mM TKI. The bars represent means and standard errors of three independent studies. Asterisk (*) represents statistical significance of the CBF-1 luciferase means between MCF-7/HER2-18 and MCF-7/Neo controls; ** represents statistical significance of the CBF-1 luciferase means between trastuzumab and IgG treatments as calculated using a two-sided Student's t-test.
Trastuzumab activates Notch-1 C Osipo et al decreased the sensitivity of MCF-7 cells to a GSI (LY411,575), decreasing the slope of the linear doseresponse curve from À410.00 in MCF-7/neo cells to À210.63 in MCF-7/HER2-18 cells (Po0.0001; Figure 6a ). Trastuzumab treatment of MCF-7/HER2-18 cells increased the slope of the curve in response to LY411,575 from À210.63 to À411.10 (Po0.0001; (Figure 6a ). Similarly, 10 mg/ml trastuzumab initially increased the slope of the linear growth curve for SKBr3 cells in response to LY411,575 from À5.3922 with IgG treatment to À25.864 (Po0.0001; Figure 6b ). However, at higher concentrations of LY411,575 with IgG treatment, the slope of the linear growth curve significantly increased to À200.25 compared to LY411,575 plus trastuzumab that was À85.871 (Po0.001; Figure 6b ). To confirm the improved efficacy of trastuzumab plus GSI, we measured cell proliferation of SKBr3 cells using a chemically distinct GSI, MRK-003. The results showed that the exponential slope of the growth curve of SKBr3 cells in response to MRK-003 with IgG was only À0.9129 compared to À3.0535 with MRK-003 plus trastuzumab (Po0.001; Figure 6c) . Moreover, the results demonstrated that only 1 mM MRK-003 was sufficient to increase the exponential slope of the SKBr3 growth curve from À0.9736 to À1.6579 in response to a TKI (Po0.05; Figure 6d ).
Trastuzumab plus a GSI promotes cell death
Cell-cycle analyses were performed to determine where in the cell cycle the combination of trastuzumab plus a GSI inhibits growth of SKBr3 and BT474 cells. The results demonstrated that 10 mM LY411,575 GSI treatment alone of SKBr3 cells decreased the percent of cells in G 0 /G 1 to 50% and S phase to 12%, but increased G 2 / M to 25% and SubG 0 to 12% compared to dimethyl sulfoxide (DMSO) vehicle (Figure 6e ). Trastuzumab treatment alone decreased percent of cells in S-phase to 15% and increased G 0 /G 1 to 75% and G 2 /M to 15% compared to IgG control (Figure 6e ). Combining trastuzumab and a GSI decreased percent of cells in G 0 /G 1 to 60%, S-phase to 10%, G 2 /M to 5%, but increased SubG 0 to 20% (Figure 6e ). Annexin V staining was performed to detect early apoptotic SKBr3 cells. The results showed that GSI alone increased the % of Annexin V-stained cells to 10% versus DMSO control (Figure 6f ). Trastuzumab alone did not induce apoptosis. In contrast, trastuzumab plus GSI increased percent of apoptotic SKBr3 cells to 20% (Figure 6f ). The exact same experimental conditions were used to analyse the cell-cycle distribution of trastuzumabsensitive and -resistant BT474 cells. GSI treatment alone did not affect the cell cycle of trastuzumabsensitive BT474 cells compared to DMSO control. Trastuzumab activates Notch-1 C Osipo et al
Trastuzumab treatment alone decreased the percent of cells in S phase to less than 5% and increased percent of cells in G 2 /M to 17% (Figure 6g ). However, trastuzumab plus GSI decreased the percent of cells in G 0 /G 1 to 70% and increased SubG 0 to 15% (Figure 6g ). In contrast, GSI alone decreased the percent of trastuzumab-resistant BT474 cells in G 0 /G 1 to 70%, S phase to 5%, but increased G 2 /M to 10% and SubG 0 to 10% (Figure 6h ). Trastuzumab did not change the cell-cycle distribution of resistant cells (Figure 6h ). However, trastuzumab plus GSI decreased percent of cells in G 0 / G 1 to 70%, S phase to 5%, G 2 /M to almost 0%, but increased SubG 0 to 25% (Figure 6h ).
Downregulation of Notch-1 sensitizes both sensitive and resistant BT474 cells to trastuzumab
The cell proliferation and cell-cycle analyses described previously suggested that inhibiting Notch-1 could increase the sensitivity of ErbB-2-positive breast cancer cells to trastuzumab and reverse resistance. To address the question of whether the increase in Notch-1 activity decreases the efficacy of trastuzumab in sensitive cells and promotes resistance in resistant cells, we knocked down Notch-1 by siRNA and performed a cell proliferation DNA content assay using increasing concentrations of trastuzumab. The data showed that although the cell proliferation of parental BT474 cells transfected with a scrambled nonspecific siRNA was decreased by trastuzumab in a dose-dependent manner, it was only decreased by 30% (Po0.001) at 20 mg/ml versus IgG (Figure 7a ). However, when parental BT474 cells were transfected with Notch-1 siRNA, there was a 30% decrease in cell proliferation in the absence of trastuzumab and growth was completely inhibited in response to 10 mg/ml trastuzumab (Figure 7a ). More importantly, cell proliferation of trastuzumab-resistant BT474 cells was decreased more than 50% with Notch-1 siRNA and completely abolished in response to 10 mg/ ml trastuzumab (Po0.0001; Figure 7b ). Similar results were observed when BT474 trastuzumab-resistant cells were treated with 10 mM LY411,575 GSI (Figure 7c ). These results suggest that increased expression and activity of Notch-1 might be a novel mechanism for 
Discussion
Our results demonstrate, to our knowledge for the first time, that overexpression of ErbB-2 in breast cancer cells suppresses Notch-1 transcriptional activity, and inhibition of ErbB-2 using either trastuzumab or a dual EGFR/ ErbB-2 TKI reactivates Notch-1 activity. Increased Notch-1 activity by trastuzumab might be responsible for trastuzumab's low efficacy in sensitive cells and, at least in some cases, for the development of resistance. The results clearly demonstrate that cell proliferation is decreased significantly more when trastuzumab is combined with either a g-secretase inhibitor (GSI) or with Notch-1 siRNA. The decrease in cell proliferation is due to a significant increase in apoptosis. The results from the findings suggest that hyperactive ErbB-2 suppresses Notch-1 signaling and ErbB-2 inhibition by either trastuzumab or TKI reactivates Notch-1 signaling, which could result in resistance. Our model predicts that ErbB-2-overexpressing breast cancer cells receive necessary growth and survival signals through ErbB-2, and do not have a requirement for Notch-1 signaling. However, upon ErbB-2 inhibition and reactivation of Notch-1 signaling, the cells become more dependent upon Notch-1 for growth and/or survival, and therefore more sensitive to Notch inhibition using a GSI or a specific Notch-1 siRNA. Cell proliferation of ErbB-2-positive breast cancer cells was almost completely inhibited and apoptosis increased with the combination of trastuzumab plus GSI.
One of the main obstacles to ErbB-2-targeted therapy for breast cancer is the fact that signaling pathways required for cell proliferation, survival or invasion are linked by multiple cross-talk mechanisms. As a result, the chronic inhibition of ErbB-2 causes the signaling network in cancer cells to reset and respond by activating other pathways that can support cancer cell proliferation and/or survival. Eventually, this leads to the selection of cancer cells (or tumor-initiating cells) that no longer rely on the ErbB-2 pathway originally targeted. Today, the only approved targeted therapies for ErbB-2-positive breast cancer are trastuzumab, a humanized monoclonal antibody directed against the ecto-domain of ErbB-2 and the recently approved dual EGFR/ErbB-2 TKI, lapatinib, which is in use for the treatment of metastatic breast cancer after relapse on trastuzumab (Geyer et al., 2006) . However, 
P<0.0005
Figure 4 Trastuzumab increases nuclear localization of Notch-1. SKBr3 (a) and MCF-7/HER2-18 (b) cells were plated at a density of 20 000 cells per well onto poly-L-lysine-coated slides containing 500 ml medium. The following day, cells were treated with immunoglobulin G (IgG) or 10 mg/ml trastuzumab for 24 h. Immunofluorescence was performed as described in 'Materials and methods' to detect Notch-1 (red) and nuclear DNA using 46-diamidino-2-phenyl indole (DAPI, blue). Merged photographs show both Notch-1 (red) and DAPI (blue). Percentage of cells staining for nuclear Notch-1 was calculated using the ratio of number of cells staining for Notch-1 in the nucleus (merged red þ blue ¼ pink) to total number of cells, times 100. SKBr3 (c) and MCF-7/HER2-18 (d) were transfected with full-length Notch-1 fused to Renilla luciferase and grown for 48 h. Cells were treated with IgG or 10 mg/ml trastuzumab. Nuclei were separated from cytoplasm and plasma membrane as described in 'Materials and methods'. Renilla luciferase activity was measured in the nuclear or cytoplasm þ plasma membrane fractions separately. The ratio of nuclear/nuclear þ cytoplasm þ plasma membrane (total) Renilla luciferase activities are plotted as means ± standard errors of three independent experiments. Asterisk (*) represents statistical significance compared to IgG control as calculated using a two-sided Student's t-test.
Trastuzumab activates Notch-1 C Osipo et al lapatinib-resistant in-vitro cell culture models have already been developed demonstrating that resistance to ErbB-2-targeted therapies might be a common occurrence (Xia et al., 2006) . Our data suggest that both short-and long-term inhibition of ErbB-2 would result in upregulation of Notch-1 signaling, a potent cell-fate determinant with tumor-initiating properties in breast epithelial cells, and possibly lead to resistance. The mechanism by which ErbB-2 overexpression suppresses Notch-1 activation remains unclear. Preliminary results showed that the Notch ligand, Jagged-1, which is overexpressed with Notch-1 in estrogen receptor-negative, basal-like and ErbB-2-positive breast tumors (Reedijk et al., 2007) is expressed but localized to submembrane endosomes in ErbB-2-overexpressing cells (data not shown). However, when ErbB-2-positive breast cancer cells were treated with trastuzumab for only 3 h, both Notch-1 and Jagged-1 accumulated to the cell surface and were excluded from early endosome antigen 1 ) were plated in six-well plates containing Iscove's minimal essential media (IMEM) supplemented with 5% fetal bovine serum (FBS) overnight. The following day, cells were treated with 10 mg/ml immunoglobulin G (IgG) control or trastuzumab (Trast) for 1, 8, 24 and 48 h. Total RNA was extracted using the RNeasy Kit and reverse transcribed to total cDNA using an Applied Biosystems' kit. Relative mRNA expression levels for Notch-1 and hypoxanthine phosphorybosyl transferase (HPRT, as a loading control) were detected by real-time PCR using the 3700 TaqMan instrument. The bars represent means ± standard errors of at least three independent experiments. Asterisk (*) represents statistical significance between means of Trast compared to IgG control. Parental, trastuzumab-sensitive BT474 cells were treated with 10 mg/ml trastuzumab for 6 months. Resistant cells were grown continuously in the presence of 10 mg/ml trastuzumab for an additional month to ensure resistant phenotype. Both sensitive and resistant cells were transfected with scrambled control small-interfering RNA (siRNA, SCB) or Notch-1 siRNA (Notch-1i) for 48 h. Total RNA from both sensitive and resistant cells was isolated and reverse transcribed to cDNA to perform TaqMan Q-RT-PCR using primers to detect endogenous Notch target gene expressions: Hey1 (c) and Deltex1 (d). (e) Western blot was performed on lysates from both sensitive (Sens) and resistant (Res) cells to detect PY-ErbB-2, total ErbB-2, Notch-1, Notch target Hes5 and b-actin for a loading control. (f) Western blot to detect Notch-1 and b-actin proteins in sensitive and resistant cells previously transfected with SCB or Notch-1i. Asterisk (*) represents statistical significance of means between resistant and sensitive cells transfected with SCB; ** represents statistical significance of means between Notch-1i and SCB control as calculated using a two-sided Student's t-test.
Trastuzumab activates Notch-1 C Osipo et al (EEA1)-positive vesicules (data not shown). These preliminary results suggested that ErbB-2 might be suppressing Notch-1 activation by deregulating Notch-1 and Jagged-1 exocytosis, endocytosis and/or recycling. We are comprehensively investigating this possible mechanism. Alternatively, it was reported recently that Notch-2 expression correlates with ErbB-2 and AKT in invasive human breast cancer (Florena et al., 2007) . Furthermore, Notch-2 has been reported to be a putative tumor suppressor in breast cancer by possibly counteracting the transcriptional activity of Notch-1 ( Figure 6 Trastuzumab or tyrosine kinase inhibitor (TKI) sensitize ErbB-2-positive breast cancer cells to a g-secretase inhibitor (GSI). MCF-7/Neo control, MCF-7/HER2-18 (a) and SKBr3 cells (b-d) were seeded in 24-well plates at a density of 15 000 cells per well in 500 ml 5% fetal bovine serum (FBS) containing Iscove's minimal essential media (IMEM) on day 0. On day 1, media containing the appropriate agents (immunoglobulin G (IgG), 10 mg/ml trastuzumab, LY411,575 GSI, MRK003 GSI or TKI) were added. Media containing freshly prepared agents were added on days 3 and 5. On day 6, DNA content (mg/ml) of each sample well was measured using the Bio-Rad Cell Proliferation Kit (Bio-Rad Laboratories) according to the manufacturer's instructions using a microplate fluorometer (MicroProbes). Graphs represent percent DNA content means (y axis) versus log of drug concentrations (x axis). Error bars represent standard errors of at least three independent experiments. Each graph was analysed for best fitting function using Sigmaplot (SPSS). Functions that best fit the experimental data were chosen based on correlation coefficients>0.80. On the basis of this criterion, graphs (a) and (b) were fitted to linear functions (y ¼ mx þ b). Linear equations are provided on each graph with numerical slopes ('m') underlined. For panel (b) the data best fit two linear functions, from 0 to 1.25 mM LY411,575, and from 1.25 to 1.75 mM. Equations and slopes are provided for each line. Graphs (c, d) were best fitted by exponential equations (y ¼ b mx ). Exponential equations for each graph are provided including numerical slope values ('m'), underlined. Statistical analysis was performed as follows: three independent growth curve experiments were performed, each in quadruplicate. Means±standard errors were computed for the slopes. Mean slopes ± standard errors were compared among different experimental conditions using two-sided Student's t-test (a ¼ 0.05). In (a) asterisk (*) represents statistical significance of slopes for MCF-7/HER2 versus MCF-7/neo; ** represents statistical significance of slopes for MCF-7/HER2 þ Trast versus MCF-7/HER2. In (b) asterisk (*) represents statistical significance of initial slopes for Trast treatment versus IgG; ** represents statistical significance of final slopes for IgG versus Trast. In (c) asterisk (*) represents statistical significance of Trast treatment versus IgG. In (d) asterisk (*) represents statistical significance of TKI þ MRK-003 versus TKI þ dimethyl sulfoxide (DMSO) control. (e, f) One hundred thousand SKBr3 cells were plated in a six-well plate using 5% FBS containing IMEM media. (g, h) One hundred fifty thousand BT474(S) (trastuzumab-sensitive) and BT474(R) (trastuzumabresistant) cells were plated in a six-well plate using 10% FBS containing IMEM media. The next day, medium containing PBS/DMSO or trastuzumab/GSI or combinations of trastuzumab and GSI were added to each well. After 48 h of treatment, cell-cycle analysis (e-h) or Annexin V (f) was performed. Bars represent means ± standard errors for three independent experiments. might inhibit Notch-1 activity in ErbB-2-positive breast cancer, which could be reversed by inhibiting ErbB-2. This potential mechanism is also currently under investigation.
What is known to date is that high-level coexpression of Notch-1 and Jagged-1 is associated with poor prognosis in breast cancer (Reedijk et al., 2005 (Reedijk et al., , 2007 Dickson et al., 2007) including ErbB-2-positive tumors (Reedijk et al., 2007) . Our data suggest that the addition of a Notch inhibitor (GSI) to chemotherapeutic regimens including trastuzumab/TKI may increase the efficacy of trastuzumab/TKI and possibly reverse or prevent resistance to ErbB-2 targeted therapies. In-vivo experiments are underway to test these hypotheses.
Materials and methods

Cell lines and constructs
SKBr3 and BT474 breast cancer cells were obtained from American Type Culture Collection. MCF-7/Neo and ErbB-2-overexpressing MCF-7 (MCF-7/HER2-18) cells were kindly provided by Dr Mien-Chie Hung (The University of Texas, MD Anderson Cancer Center, Houston, TX, USA) and were previously described (Benz et al., 1992) . BT474 resistant cells Trastuzumab activates Notch-1 C Osipo et al were cultured with 10 mg/ml trastuzumab (Loyola University Medical Center Pharmacy) for 6 months. All cells were cultured in Iscove's minimal essential media (IMEM) with 5% (SKBr3) or 10% (BT474) fetal bovine serum (FBS), 100 mM nonessential amino acid and 1 mM sodium pyruvate. Notch constructs and CBF-1 luciferase reporter assays have been previously described (Weijzen et al., 2002) . The plasmid coding for mouse full-length Notch-1 tagged at the C terminus with Renilla luciferase (Vooijs et al., 2004) was a kind gift from Dr Raphael Kopan (Washington University, St Louis, MO, USA).
Drugs and chemicals g-Secretase inhibitors LY411,575 was synthesized by Dr Todd Golde (Mayo Clinic, Jasksonville, FL, USA) and MRK-003 was provided by Dr Peter Strack (Merck Inc.). A dual EGFR/ErbB-2 TKI (4557W; EMD Biosciences San Diego, CA) was purchased. They were dissolved in DMSO, aliquoted and stored at À80 1C until use. Lyophilized trastuzumab (220 mg) was purchased (Loyola University Medical Center Pharmacy), resuspended in 10 ml sterile phosphate-buffered saline (PBS), aliqouted and stored at À80 1C until use.
Western blotting
Cells were lysed in radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 25 mM b-glycerophosphate, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml Figure 7 Notch-1 small-interfering RNA (siRNA) or g-secretase inhibitor (GSI) restores sensitivity of BT474 resistant cells to trastuzumab. Both BT474 trastuzumab-sensitive (a) and -resistant cells (b) were transfected with a scrambled control siRNA (SCB) or Notch-1 siRNA (Notch-1i) and grown in medium containing increasing concentrations of trastuzumab (Trast; 0-20 mg/ml). At day 6, a DNA content assay was performed to measure cell proliferation (a, b, left panels). In an experiment conducted simultaneously, Notch-1 and b-actin proteins were detected by western blot (a, b, right panels) to confirm that Notch-1 siRNA downregulated Notch-1 protein. (c) BT474 resistant cells were treated with trastuzumab alone or in combination with LY411,575 for up to 6 days. DNA-based proliferation assays was conducted on day 6. Asterisk (*) represents statistical significance of Trast treatment versus immunoglobulin G (IgG) control in (a); ** represents statistical significance of Notch-1i versus SCB in (b); * represents statistical significance between LY411,575 and dimethyl sulfoxide (DMSO) control in (c).
Trastuzumab activates Notch-1 C Osipo et al aprotinin and 1 mg/ml leupeptin). Western blotting was performed as described previously (Osipo et al., 2003) . Densitometry was performed to measure expression levels of PY-ErbB-2 with respect to total ErbB-2 protein. The FujiFilm Las-3000 imager was used to visualize detected protein. Antibodies used were: phosphorylated tyrosine (Y1248)-specific ErbB-2 (Ab-18, Neomarkers, Fremont, CA, USA), ErbB-2 (AB-17, Neomarkers), Notch-1 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), activated Notch-1 (Cell Signaling, Charlottesville, VA, USA), Hes5, Hey1 and Hes1 (Santa Cruz Biotechnology), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology) and bactin (Sigma-Aldrich, St Louis, MO, USA).
Real-Time PCR Total RNA was extracted from cells using the RNeasy kit (Qiagen, Valencia, CA, USA). Total RNA was reversetranscribed to total cDNA using the TaqMan Reverse Transcriptase Kit (Applied Biosystem, Foster City, CA, USA) according to the manufacturer's instructions. Real-time PCR was performed on cDNAs to detect relative expression of Notch-1 (forward primer: 5 0 -CGGGTCCACCAGTTTGA ATG-3 0 , reverse primer: 5 0 -GTTGTATTGGTTCGGCAC CAT-3 0 ), Hey1 (forward primer: 5 0 -AGCTCCTCG GACAG CGAGCTG-3 0 , reverse primer: 5 0 -TACCAGCCTTCTCAG CTCAGACA-3 0 ), Deltex1 (forward primer: 5 0 -CAGTTTCG CCAGGACACAG-3 0 , reverse primer: 5 0 -GCAGATGTCCA TATCGTAGGC-3 0 ) and hypoxanthine-guanine phosphoribosyl transferase (HPRT; forward primer: 5 0 -ATGAACC AGGTTATGACCTTGA T-3 0 , reverse primer: 5 0 -CCTGT TGACTGGTCATTACAATA-3 0 ) for a loading control.
Nuclear fractionation
SKBr3 cells previously transfected with full-length Notch-1 fused at the C terminus with Renilla luciferase were grown to 60% confluence and treated with IgG control or 10 mg/ml trastuzumab for 24 h. Cells were harvested and washed in PBS, resuspended and lysed in 0.32 mol/l sucrose buffer with 3 mmol/l CaCl2, 2 mmol/l magnesium acetate, 0.1 mmol/l EDTA, 10 mmol/l Tris (pH 8.0), 1 mmol/l DTT, 0.5% NP40 and protease inhibitors centrifuged at 1000 g. The supernatant was used as the cytoplasmic fraction. The resuspended pellet was centrifuged on a 1.8 mol/l sucrose cushion with 5 mmol/l magnesium acetate, 0.1 mmol/l EDTA, 10 mmol/l Tris (pH 8.0), 1 mmol/l DTT and protease inhibitors at 30 000 g for 45 min. The resulting nuclear pellet was lysed in 15 ml buffer 2 (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.9, 0.4 M NaCl, 1.5 mM MgCl 2 , 25% glycerol, 0.2 mM EDTA, 1 mM DTT and 0.5 mM phenylmethylsulphonyl fluoride, PMSF). Lysates were diluted in 50-70 ml buffer 3 (20 mM HEPES, pH 7.9, 50 mM KCl, 20% glycerol, 0.2 mM EDTA, 1 mM DTT and 0.5 mM PMSF). Luciferase activity was measured as described below.
Transfection and luciferase assays Cells were transfected with a CBF-1 luciferase reporter construct using FuGene 6 (Roche Diagnostic, Indianapolis, IN, USA) according the manufacturer's instructions. Cells were transfected with scrambled or Notch-1-specific siRNA (AAGTGTCTGAGGCCAGCAAGA) from Santa Cruz Biotechnology using Oligofectamine according the manufacturer's instructions. Luciferase assay was performed using the DualLuciferase assay (Promega, Madison, WI, USA) using pRL-TK (Renilla luciferase) as internal control. Luminescence was read using the Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale, CA, USA).
Immunofluorescence
SKBr3 and MCF-7/HER2 cells were grown on glass slides for 48 h in 5% FBS containing IMEM and treated with IgG or trastuzumab. At the end of the treatment, cells were rinsed twice in PBS and fixed in cold methanol. Staining for Notch-1 was performed using 1 mg/ml C-20 antibody (Santa Cruz Biotechnology) and 20 mg/ml AlexaFluor 555 labeled anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA). DAPI (46-diamidino-2-phenyl indole) was used to counter stain nuclei. A fluorescence microscope was used to detect Notch-1 and DAPI fluorescence.
Cell growth assay SKBr3 wild-type, MCF-7/Neo, MCF-7/HER2-18, trastuzumab-sensitive BT474 and trastuzumab-resistant BT474 cells were seeded in 24-well plates at a density of 15 000 cells in 500 ml 5% FBS containing IMEM on day 0. On day 1, media containing the appropriate agents were added. Media containing freshly prepared agents were added on days 3 and 5. On day 6, DNA content (mg/ml) of each sample well was measured using the Bio-Rad Cell Proliferation Kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions using a microplate fluorometer (MicroProbes, Washington, DC, USA).
Cell-cycle analysis SKBr3 cells were plated in a six-well plate at a density of 100 000 using 5% FBS containing IMEM media. BT474(S) and BT474(R) cells were plated at a density of 150 000 in a sixwell plate using 10% FBS containing IMEM media. The next day, medium containing PBS/DMSO or trastuzumab/GSI or combinations of trastuzumab and GSI were added to each well. After 48 h of treatment, cell-cycle analysis was performed as described previously (Weber et al., 2003) .
Annexin V SKBr3 cells were plated in 10 cm 2 plate at a density of 500 000 per plate. Cells were treated with 20 mg/ml trastuzumab or IgG and/or 20 mM LyY411,575 for 48 h. After 48 h of treatment, Annexin V staining was performed as described previously (Weber et al., 2003) .
Statistical analysis
Statistical analysis of at least three independent experiments was performed using a two-sided Student's t-test when comparing two groups. Linear regression or exponential analyses were performed on DNA assay-based cell proliferation assays. The slopes of three independent experiments were analysed for significance. P-values o0.05 were considered statistically significant.
